A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Inclusion Criteria:

1. Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent, and/or unresectable) with measurable disease or metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on CT/MRI for prostate cancer and have at least 1 lesion accessible for biopsy. For Part 2B participants with HCC, intermediate disease is allowed.
2. Eastern Cooperative Oncology Group Performance Status of 0 or 1
3. Must have received, and then progressed, relapsed, or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting according to tumor type, if such a therapy exists
4. Prior anti-cancer treatments such as chemotherapy, radiotherapy, or hormonal are permitted for some participants
5. Willing and able to comply with all study procedures

Exclusion Criteria:

1. Primary central nervous system (CNS) malignancies, tumors with CNS metastases as the only site of disease or active brain metastases will be excluded
2. Other active malignancy requiring concurrent intervention
3. Prior organ allograft
4. Active, known, or suspected autoimmune disease

Other protocol-defined inclusion/exclusion criteria apply